康莱特联合重组人白介素-2灌注治疗恶性胸腔积液临床观察

Clinical Observation of Kanglaite Injection Combined with Recombinant Human Interleukin-2 in the Treatment of Malignant Pleural Effusion

目的:康莱特的天然抗癌活性物质受到临床的广泛关注,本研究旨在观察康莱特联合重组人白介素-2灌注治疗恶性胸腔积液的效果及患者生活质量改善情况。方法:选取本院2016年6月-2017年12月收治的肺癌晚期伴胸腔积液的患者80例作为研究对象,按照随机数字表法将其分为观察组和对照组,各40例。观察组给予重组人白介素-2联合康莱特胸腔灌注治疗,对照组仅给予重组人白介素-2胸腔灌注治疗,治疗4周后,比较两组胸腔积液疗效、生活质量以及毒副反应发生情况。结果:治疗4周后,观察组总有效率为87.5%,完全缓解(CR)、部分缓解(PR)、病情稳定+疾病进展(SD+PD)分别是13例(32.5%)、22例(55.0%)和5例(12.5%)。对照组总有效率为67.5%,CR、PR、SD+PD分别是9例(22.5%)、18例(45.0%)和13例(32.5%)。观察组总有效率明显高于对照组,差异有统计学意义(X^2=4.587 8,P=0.032 2)。观察组KPS评分改善情况明显优于对照组,差异有统计学意义(P<0.05)。两组毒副反应发生情况比较,差异均无统计学意义(P>0.05)。结论:康莱特联合重组人白介素-2可明显提高肺癌并恶性胸腔积液的疗效,毒副反应小,显著改善患者生活质量,值得临床推广。

Objective:The natural anti-cancer active substances of Kanglaite Injection were widely concerned by the clinic.The purpose of this study was to observe the effect of Kanglaite Injection combined with Recombinant Human Interleukin-2 perfusion in the treatment of malignant pleural effusion and the improvement of patients'quality of life.Method:A total of 80 patients with advanced lung cancer complicated with pleural effusion admitted in our hospital from June 2016 to December 2017 were selected as the study objects.According to the random number table method,They were divided into observation group and control group,40 cases in each group.The observation group was given Recombinant Human Interleukin-2 plus Kanglaite Injection pleural perfusion treatment,the control group was only given Recombinant Human Interleukin-2 pleural perfusion treatment.After treatment 4 weeks,the efficacy,quality of life and toxic and side effects between the two groups were compared.Result:After treatment 4 weeks,the total effective rate in the observation group was 87.5%,the complete remission,partial remission and stable disease+disease progression were 13 cases(32.5%),22 cases(55.0%)and 5 cases(12.5%)respectively.The total effective rate in the control group was 67.5%,9 cases(22.5%),18 cases(45.0%)and 13 cases(32.5%)had complete remission,partial remission and stable disease+disease progression respectively.The total effective rate of the observation group was significantly higher than that of the control group,the difference was statistically significant(χ2=4.587 8,P=0.032 2).The improvement of KPS score in the observation group was significantly better than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion:Kanglaite Injection combined with Recombinant Human Interleukin-2 can significantly improve the efficacy of lung cancer with malignant pleural effusion,has small toxic and side effects and significantly improve the quality of life of patients,which is worthy of clinical promotion.